The drug has the proposed trade name Rikelta. The results are compiled from two Phase IIb double-blind, randomized, parallel-group, placebo-controlled dose ranging studies. The two studies involved 365
OSI-7904L is a liposomal formulation of a potent inhibitor of the enzyme thymidylate synthase with unique properties. The liposomal nature of the drug allows a more convenient dosing
The FDA assigns priority review to drugs that, if approved, would offer major advances in treatment or would provide treatment to patients where no adequate therapy exists. Priority
This latest round of funding was conducted with financial advice from Seaview Securities and advised by Fox Rothschild Technology and Venture Finance Group. The funds will be used
The study met its primary endpoint for seizure reduction over placebo during the treatment period (p=0.038). The median percent reduction of partial onset seizures in the extended-release levetiracetam
The results of the clinical trial demonstrated that the study met its primary safety endpoint of superiority in freedom from major adverse events at 30 days, and the
In the trial, 181 patients received a single dose of one of three doses of TC-2696 or ibuprofen or placebo following third molar extraction surgery. TC-2696 did not
In Rotavirus Efficacy and Safety Trial (REST), Rotateq demonstrated 98% efficacy against severe cases of rotavirus gastroenteritis and 74% of all rotavirus gastroenteritis cases caused by rotavirus serotypes
The interim results include 10 patients who had completed 4-weeks of treatment equally divided between pegylated interferon (alfa-2b) plus ribavirin (PR) and celgosivir 400mg QD plus PR (PRC).
According to Auriga, the new product combines one of the most frequently prescribed drug classes for this condition, in a unique dosage form previously not available. The product
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.